Morrison Foerster is an international law firm with lawyers practicing throughout the United States, Asia, and Europe. Click to discover more.

mofo_share_image.jpg

Morrison Foerster

common-default.jpeg

Terms / Notices

Cookies

Privacy Policy

Reporting Hotline

Attorney Advertising

Alumni

  Linkedin

MoFo LinkedIN

  Facebook

MoFo Facebook

YouTube

MoFo Youtube

Morrison Foerster - Footer

MoFo Advises Veracyte on Acquisition of Convergent Genomics

You have not solved the recaptcha challenge yet or session expired, try again.

Email Disclaimer

Disclaimer

Unsolicited e-mails and information sent to Morrison Foerster will not be considered confidential, may be disclosed to others pursuant to our <a href="https://www.mofo.com/about/privacy-policy.html">Privacy Policy</a>, may not receive a response, and do not create an attorney-client relationship with Morrison Foerster. If you are not already a client of Morrison Foerster, do not include any confidential information in this message. Also, please note that our attorneys do not seek to practice law in any jurisdiction in which they are not properly authorized to do so.

Feedback

mofo-logo-2022.svg

People

Capabilities

Resources

About

Community

Offices

Careers

Stay Connected

Morrison Foerster advised Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, on its acquisition of Convergent...

<h3>Sorry, we weren’t able to find the terms you entered.</h3>Please try a different term or keyword.

People

Capabilities

Resources

Not Found Cards

About Morrison Foerster

people-default-header-desktop.jpg

people-default-header-mobile.jpg

Default Meta Data

Morrison Foerster advised Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, on its acquisition of Convergent Genomics, Inc. The acquisition adds Convergent Genomics’ UroAmp platform, including its proprietary urinary tumor DNA (utDNA) technology, to Veracyte’s product portfolio, and positions Veracyte to deliver powerful genomic insights from urine, tissue, and blood to help guide bladder cancer care across the patient journey. The transaction closed on September 14, 2026.UroAmp, a urinary tumor DNA testing platform, has been clinically validated in non-muscle invasive bladder cancer (NMIBC), including therapy-response monitoring and post-treatment surveillance.The MoFo team was led by corporate partners Jim Krenn and Shiri Shenhav, and of counsel Anthony Krueger. The broader team included technology transactions partner Matthew Ferry, capital markets of counsel Emily Beers, employment + labor partner Michael Schulman, executive compensation partner Joshua Lerner, patent partner Karen Potter, IP litigation partner Aaron Fountain, privacy partner Melissa Crespo, regulatory partner Brigid Bondoc, government contracts partners Locke Bell and Tina Reynolds, antitrust partner Megan Gerking, and tax partner Brian Radigan.Read more about the transaction in Veracyte’s <a href="https://investor.veracyte.com/news-releases/news-release-details/veracyte-acquires-convergent-genomics-expanding-its-urology" target="_blank">press release</a>.

MoFo Advises Veracyte on Acquisition of Convergent Genomics

Sign Up

Jim advises private and public companies and investors in significant business transactions, from formation through liquidity. His practice focuses on mergers and acquisitions, venture capital financings, and emerging company counseling. His clients span a broad range of industries, with a concentration on life sciences and technology companies.Jim represents buyers and sellers in private and public acquisitions across numerous transaction structures. His experience includes equity purchases, asset purchases, mergers, acquisitions, divestitures, cross-border transactions, and auctions. He has advised on deals ranging from several million dollars to more than $1 billion.Jim counsels emerging and established life sciences and technology companies on equity financings and general corporate matters. He also represents angel, corporate, and venture capital investors making investments in those companies. He has advised clients in hundreds of venture capital financings, from seed rounds to later-stage rounds exceeding $100 million.Jim represents public companies on public offerings, other capital markets transactions, and SEC reporting and compliance. He also advises boards of directors on corporate governance matters.Jim serves on the leadership team of MoFo’s Life Sciences + Healthcare Group and on the firm’s Artificial Intelligence steering committee. He also serves on the board of directors of the San Diego Entrepreneurs Exchange.<h4>Representative Transactions</h4><h5>Mergers and Acquisitions</h5><ul><li>ACEA Biosciences, a medical instruments company, in its sale to Agilent Technologies (NYSE: A) for $250 million.</li><li>Adicet Bio (Nasdaq: ACET), a biopharmaceutical company, in its merger with a wholly owned subsidiary of resTORbio (Nasdaq: TORC) to create a combined publicly traded biotechnology company.</li><li>Alaska Energy & Resources Company, a parent company of a regulated electric utility in Alaska, in its $170 million sale to Avista (NYSE: AVA).</li><li>Astute Medical, a medical diagnostic company, in its $90 million sale to bioMérieux (EPA: BIM).</li><li>B. Riley Financial (Nasdaq: RILY), a diversified financial services company, in its $53 million private placement and merger with investment banking firm B. Riley & Co.</li><li>Biotix, a private equity-backed developer and manufacturer of laboratory consumables and liquid handling solutions, in its sale to Mettler-Toledo (NYSE: MTD).</li><li>California Cryobank, a private equity-backed leader in reproductive tissue donor services and stem cell banking, in multiple acquisitions.</li><li>Clean Energy Fuels (Nasdaq: CLNE), a provider of natural gas as an alternative fuel for vehicle fleets, in its sale for up to $180 million of components of its renewable natural gas business to BP (NYSE: BP).</li><li>Cogent (Nasdaq: COGT), a biometric identification solutions provider, in its $943 million sale to 3M (NYSE: MMM).</li><li>Deere & Company (NYSE: DE), an agricultural, construction, and forestry machinery corporation, in its planned acquisition of the precision planting unit of Monsanto (NYSE: MON).</li><li>Dosatron International, a distributor of water-powered dosing pumps and systems, in connection with its sale to Ingersoll Rand (NYSE:IR).</li><li>Gillco, a leading specialty ingredient provider, in its sale to Azelis (BR: AZE).</li><li>Mentor (NYSE: MNT), a leading supplier of medical products for the global aesthetic market, in its $1.12 billion sale to Johnson & Johnson (NYSE: JNJ).</li><li>Mitchell International, a developer of smart technology solutions, in its acquisition of Cogent Works.</li><li>MyChem, a provider of ultra-pure nucleotides, in connection with its sale to Maravai (NASDAQ: MRVI) for $240 million at closing with potential additional consideration.</li><li>Protomer Technologies, a biotechnology company, in its sale to Eli Lilly and Company (NYSE: LLY) with a potential value of over $1 billion with successful achievement of future development and commercial milestones.</li><li>Rakuten Medical, a biotechnology and medical device company, in its acquisition of Medlight SA and its acquisition of key assets and manufacturing technology from Li-Cor Biosciences.</li><li>Safebuilt Insurance Services, a managing general agent and insurance technology company, in its sale to Integrated Specialty Coverages.</li><li>Sequlite Genomics, a DNA sequencing firm, in connection with its sale to Fapon Biotech, a diagnostic technology company.</li><li>Tendo, a digital health software company, in its acquisition of MDsave, a healthcare marketplace company.</li><li>Wavestream, a provider of high-power solid-state amplifiers, in its $137 million sale to Spacenet, a subsidiary of Gilat Satellite Networks (Nasdaq: GILT).</li></ul><h5>Equity Financings</h5><ul><li>9amHealth, a provider of virtual diabetes care, in its $4 million Series Seed financing and $16 million Series A financing.</li><li>ACEA Biosciences, a developer of cell analysis instrumentation technologies, in its $30 million Series E Preferred Stock financing.</li><li>Adicet Bio, a biopharmaceutical company, in its Series A financing of up to $51 million, and $80 million Series B financing.</li><li>Astute Medical, a medical diagnostic company focused on high-risk medical conditions and diseases, in over $200 million of equity and debt financings.</li><li>Bidra as an investor in multiple equity financings.</li><li>Biolumic, an agtech company, in its $13.5 million Series B financing.</li><li>California Cryobank, a private equity-backed leader in reproductive tissue donor services and stem cell banking, in multiple equity and debt financings.</li><li>Carlsmed, a medtech company pioneering AI-enabled personalized spine surgery solutions, in its $10 million Series A financing, $30 million Series B financing, $64.5 million Series C financing and $100.5 million initial public offering.</li><li>Corner Therapeutics, a biotech company, in its $54 million Series A financing.</li><li>Crinetics (Nasdaq:CRNX) as a strategic investor in Radionetics Oncology’s $52.5 million Series A financing.</li><li>Crinetics(Nasdaq:CRNX) in its $350 million PIPE financing, at-the-marketing offering of up to $350 million, $575 million underwritten public offering and $350 million underwritten public offering.</li><li>Forward Ventures as an investor in multiple equity financings, convertible debt financings, and M&A transactions.</li><li>Foxen, a provider of financial technology solutions for the real estate industry, in its $44 million Series A financing.</li><li>Greenoaks Capital Partners and its affiliates as investors in multiple equity financings, debt financings, and secondary transactions.</li><li>GroupSolver, an artificial intelligence market research platform, in multiple preferred stock financings.</li><li>Hume.ai, an artificial intelligence company, in multiple preferred stock financings.</li><li>Oak Investment Partners as an investor in multiple preferred stock financings.</li><li>OrbiMed as an investor in multiple equity financings, debt financings, and M&A transactions.</li><li>Petuum, an artificial intelligence and machine learning software infrastructure provider, in its $93 million Series B financing.</li><li>Pi Health, an AI-enabled health technology and clinical research company, in its spin-out from BeiGene, Ltd. and $35 million Series A financing.</li><li>Perceptive Advisors as an investor in multiple financings and transactions.</li><li>Presight Capital as an investor in multiple equity financings.</li><li>RA Capital as an investor in multiple equity financings.</li><li>Rakuten Medical, a biotechnology and medical device company, in over $800 million of debt and equity financings.</li><li>Rubi Laboratories, a company focused on converting carbon emissions into textiles, in multiple equity financings.</li><li>Softbank affiliates as investors in multiple equity financings.</li><li>Solarflare Communications, a technology company, in over $200 million of equity and debt financings.</li><li>Tendo Systems, a HealthTech software company, in its $20 million financing from Vistara.</li><li>Tutor Intelligence, an artificial intelligence robotics company, in its $34 million Series A financing.</li><li>VoloAgri, an ag-tech company, in over $150 million of equity financings.</li><li>Western Digital Capital as an investor in multiple preferred stock financings.</li></ul>

Jim Krenn

Chair of Emerging Companies + Venture Capital Practice

Shiri Shenhav is a partner in the Transactions Department and the Mergers + Acquisitions Group based in Palo Alto. Shiri maintains a corporate transactional practice focusing on mergers and acquisitions and equity investments in the technology industry for public and private companies.Shiri regularly assists strategic buyers and private equity funds and their portfolio companies in a variety of domestic and cross-border transactions, including deal structuring and mechanics, stock and asset purchases, mergers, divestitures, and spin-offs. Shiri also regularly represents companies with respect to their equity investments, joint ventures, and other strategic transactions, as well as general corporate counseling.As an accomplished attorney certified in California and in Israel, Shiri has extensive experience representing multinational corporations and funds in cross-border transactions involving Israeli aspects. Shiri also co-leads the firm’s AI M&A Initiative.Shiri is fluent in Hebrew.<h4 dir="ltr">Representative Experience</h4><ul dir="ltr"><li>SoftBank in connection with its acquisition of Berkshire Grey.</li><li>Vontier Corporation in its sale of Global Traffic Technologies to Miovision.</li><li>Walmart in its acquisitions of Art.com, Aspectiva, BareWeb, CareZone, Eloquii, MeMD, and Zeekit.</li><li>Zivelo in its acquisition by VeriFone.</li><li>Unity Technologies in its acquisition of RestAR.</li><li>Alpine Investors and its managed IT services and software platform Evergreen Services Group in connection with the acquisitions of Alliance Solutions Group, Global Wave Group, and Telco Experts.</li><li>Alpine Investors in its acquisition of Ethisphere. </li><li>Astroscale U.S., the U.S. unit of Astroscale Holdings, in its acquisition of certain the intellectual property and other assets and proposed hiring of certain members of the staff of Effective Space Solutions R&D. </li><li>Gryphon Investors and RegEd in the acquisition of ComplianceMAX and FIRE Continuing Education businesses from National Regulatory Services.</li><li>Mirantis in its acquisition of the Docker Enterprise platform business from Docker.</li><li>Rubicon Technology Partners in its strategic majority investment in the merger of EverTrue and ThankView.</li><li>Peer5 in its sale to Microsoft Corporation.</li><li dir="ltr">Protean Electric in its acquisition by National Electric Vehicle Sweden AB.</li></ul>

Shiri Shenhav

Partner

Anthony Krueger is of counsel in the Emerging Companies + Venture Capital practice based in the firm’s Austin office.Anthony represents high-growth startups and the investors who fund them, guiding clients through every stage of the company lifecycle—from formation and seed financings to growth equity rounds and strategic exits.Anthony regularly counsels founders, management teams, and venture capital funds on structuring, negotiating, and executing capital-raising transactions. His practice also includes advising on mergers and acquisitions involving venture-backed companies, where he draws on his experience handling both buy-side and sell-side deals across the technology, AI, defense tech, and life sciences sectors.In addition to his client work, Anthony is active in Austin’s dynamic startup ecosystem and contributes to MoFo’s broader ECVC initiatives. He is actively involved in industry events and is a frequent speaker on legal issues and fundraising for startups at universities and startup-focused events in the Austin, Texas.Anthony served as a judicial intern for the Honorable Helene N. White in the United States Court of Appeals for the Sixth Circuit and as a judicial intern for the Honorable Susan G. Braden in the United States Court of Federal Claims.

Anthony Krueger

Of Counsel

Brandon Dennis is an associate in Morrison Foerster’s New York office and a member of the firm’s Mergers & Acquisitions Group.His experience includes mergers and acquisitions, minority investments, joint ventures, and corporate governance matters. He has also advised clients on transaction structuring, due diligence, closing matters, and post-closing integration and operational issues.Prior to joining Morrison Foerster, Brandon was an associate at another leading law firm, where he represented private equity sponsors, financial institutions, and strategic buyers and sellers in a variety of domestic and cross-border transactions.Brandon earned his J.D from the George Washington University Law School and his B.A. from Cornell University.

Brandon Dennis

Associate

Ludovica Gardani-Menendez is an associate in the firm's Corporate Practice, focusing her practice on advising clients on complex domestic and cross-border transactions, with an emphasis on M&A and private equity transactions, both in the United States and Latin America.Ludovica advises clients in a broad range of corporate matters, including strategic mergers, acquisitions, joint ventures, growth equity and venture capital investments, and divestitures, across a wide variety of industry sectors, including technology; finance; consumer and retail; defense and government services; food and agriculture; business services; technology; and industrials.Ludovica graduated from University of Miami School of Law where she was Executive Editor of the Business Law Review.<h4>Representative Experience</h4><ul><li>Represented Petlove&Co. in connection with its financing round with existing major investors, Tarpon, SoftBank, L Catterton, Porto Seguro and Monashees, and a new initial investment by Riverwood Capital. This is the largest financing round in Petlove&Co’s history.</li><li>Represented SoftBank Latin America Fund in connection with a Series C funding round in Addi, a fintech startup based in Bogota, Colombia that offers buy-now-pay-later technology.</li><li>Represented Inchcape, the leading global independent multi-brand automotive distributor and retailer, in its cash-free and debt-free £47 million acquisition of Autolider, a distributor of Daimler brands in both Uruguay and Ecuador.</li></ul>

Ludovica Gardani é associada da área empresarial. Ela assessora clientes nos Estados Unidos e na América Latina em fusões e aquisições, joint ventures, transações de valores mobiliários e de mercado de capitais e ofertas públicas e privadas.Ludovica trabalha com empresas públicas e privadas em investimentos estratégicos, financiamentos e licenciamentos cross-borders em uma ampla gama de indústrias, incluindo tecnologia, varejo, infraestrutura e tecnologia financeira. Ela também representa empresas em relação a uma ampla gama de questões sobre valores mobiliários, como ofertas públicas e privadas, obrigações de reporte da U.S. Securities and Exchange Commission (SEC) e ofertas de acordo com a Regra 144A e o Regulamento S.Ludovica se formou na Faculdade de Direito da Universidade de Miami, onde foi editora executiva da Business Law Review.<h4>Experiência Representativa</h4><ul><li>Representou a Inchcape, líder global independente na distribuição e varejo de carros multimarcas, na aquisição, por £ 47 milhões, da Autolider, distribuidora das marcas da Daimler no Uruguai e no Equador.</li></ul>

Ludovica Gardani es asociada en el Departamento Corporativo de la firma. Asesora a clientes en los Estados Unidos y América Latina sobre fusiones y adquisiciones, empresas conjuntas (joint ventures), transacciones de valores y mercado de capitales, y ofertas públicas y privadas.Ludovica trabaja con empresas públicas y privadas en inversiones estratégicas, financiamientos y licencias transfronterizas en una amplia gama de industrias, que incluyen tecnología, comercio minorista, infraestructura y tecnología financiera. También representa a empresas en relación con una amplia gama de asuntos de valores, tales como ofertas públicas y privadas, obligaciones de informes de la SEC y ofertas de conformidad con la Regla 144A y el Reglamento S.Ludovica se graduó de la Facultad de Derecho de la Universidad de Miami, donde fue Editora Ejecutiva del Business Law Review.<h4>Experiencia Representativa</h4><ul><li>Representó a Inchcape, el distribuidor y comerciante automotriz independiente líder a nivel mundial, en su adquisición de Autolider, un distribuidor de las marcas Daimler en Uruguay y Ecuador por £ 47 millones.</li></ul>

Ludovica Gardani-Menendez

Matt Ferry is a partner in the San Diego office and a member of the firm’s Technology Transactions Group, advising innovative and mission-driven life sciences and frontier technology companies.Matt has more than a decade of experience in structuring, drafting, negotiating, and executing strategic transactions where intellectual property (IP), technology, data, and information assets drive the deal. Matt is passionate about advising innovative companies—from startups to large enterprises and nonprofits—that are developing technologies and solutions to improve peoples’ lives and address global challenges. His practice primarily focuses on clients across the life sciences and technology sectors, including:<ul><li>Pharmaceuticals and biotechnology (including small molecule pharmaceuticals, biologics, nanotherapeutics, drug discovery, antibodies, cell and gene therapy, CRISPR and other gene editing technologies, drug delivery, immunology, and oncology);</li><li>Medtech and healthtech (including medical devices, digital health, and other forms of software and hardware in diagnostic and therapeutic applications);</li><li>Food and agriculture (including in plants and crop sciences, agriculture and farming, alternative proteins, animal and plant production, food products and consumer goods, consumer packaged goods, and vitamins and supplements);</li><li>Cleantech (including renewable energy, biofuels, plastic recycling and carbon capture); and</li><li>Artificial intelligence/machine learning and their applications (including uses of generative AI, large language models, natural language processing, computer vision, predictive analytics, AI-enabled drug discovery, and AI applications in life sciences, agriculture, and clean technology).</li></ul>Matt’s clients value his responsiveness, his business-minded approach, and his ability to serve as a trusted advisor for strategic transactions. He leverages his previous experience in patent prosecution and IP litigation, as well as his deep interest in science and technology, to provide a holistic perspective and overall business strategy for his clients’ transactions.He advises clients in connection with:<ul><li> Commercial contracts across all stages of technology and product life cycles, from early-stage research and development through commercialization and post-market, including strategic alliances and collaborations, and co-development, asset sale and purchase, research and development, supply, manufacturing, and distribution, clinical trial, data sharing and licensing, service, and material transfer agreements.</li><li>Patent and technology license agreements in industry-to-industry, academic-to-industry, and government-to-industry settings.</li><li>IP and commercial contract matters that arise in connection with larger corporate transactions, including mergers and acquisitions, venture capital investments, joint ventures, spin-offs, SPACs, IPOs, and strategic investments, with a focus on IP and technology diligence and the drafting and negotiation of IP-related ancillary agreements, such as transition services agreements, IP assignment agreements, and license-back arrangements.</li><li>Early-stage company IP counseling and hygiene, including invention assignment agreements and IP protection strategies.</li></ul>To assist his clients, Matt draws on his technical knowledge that he developed in his undergraduate work at University of California, Berkeley, his graduate work at the California Institute of Technology, and his hobbyist scientific pursuits, including in physics, software, microwave instrumentation, and optics.<h4>Representative Transactions</h4><h5>Pharmaceuticals and Biotechnology</h5><ul><li>A multinational investment firm in its joint venture with a large public pharmaceutical company to source, develop, and commercialize therapeutic candidates.</li><li>A large institutional life sciences investor in its royalty purchase agreements.</li><li>A venture-backed biotech startup in its cross-border license and option agreement for radiotherapy technology.</li><li>A non-profit medical research organization in its license and collaboration agreements with various partners, including universities and for-profit institutions. </li><li>Eton Pharmaceuticals, Inc. in its acquisition of Galzin®, a small molecule treatment for an ultra-rare disease from Teva Pharmaceuticals.</li><li>A multinational pharmaceutical company in its manufacturing agreements.</li><li>A public mRNA technology company in its patent licensing strategy and evaluation agreements.</li><li>Eton Pharmaceuticals, Inc. in connection with its asset sale of several of its branded and generic injectable products to Dr. Reddy’s Laboratories.</li><li>A public pharmaceutical company in its purchase of three product lines from a Fortune 500 public pharmaceutical company.</li><li>A public pharmaceutical company in its sale of three product lines to a private equity-backed purchaser.</li><li>A public pharmaceutical company in numerous patent and technology asset purchases and sales, exclusive licensing arrangements, commercial alliances, and co-promotion agreements.</li><li>A public pharmaceutical company in several patent and technology asset purchases and sales, including its sale of three product lines focused on rare neurological diseases and associated assets to a private purchaser.</li><li>A venture-backed pharmaceutical company focused on treating rare diseases in China in several exclusive license and supply agreements.</li><li>A U.S. academic institution in numerous patent and technology exclusive licensing agreements, sponsored research agreements, option agreements, and term sheet negotiations.</li><li>A nanotherapeutic company in numerous research and collaboration agreements and licensing agreements.</li><li>A CRISPR-based company in numerous evaluation agreements, material transfer agreements, and collaboration agreements.</li><li>A startup company in its gene modification research agreement templates.</li></ul><h5>Medical Devices and Health Technology</h5><ul><li>A neurotech startup in its license and commercialization agreement with a large, public medical device company.</li><li>A medical device startup in its several exclusive patent and technology license agreements with a leading academic institution and its clinical trial agreements.</li><li>A digital health company in its collaboration agreement with a global distributor.</li><li>A medical device company in its multisite clinical trial agreements.</li><li>A public medical device company in its exclusive license and distribution agreement with a global medical device distributor.</li><li>A medical device incubator in its form technology and service agreements, patent license agreement from an academic institution, and sublicense agreements.</li><li>A public medical device company in its patent purchase from an individual physician.</li><li>A medical device company in its multi-country distribution agreements.</li></ul><h5>Food + Ag and AgTech</h5><ul><li>A leading berry company in its complex cross-border settlement and license agreement.</li><li>A Brazilian trait company in its cross-border commercial and IP licensing agreements.</li><li>A university spinout in its renegotiation of its university license agreement, sublicense agreements, and commercial partnerships.</li><li>An innovative plant protein startup in all forms of its commercial contracts and licensing, including its university research agreements, grower agreements, evaluation agreements, and material transfer agreements.</li><li>A plant genomics and gene editing company in its strategic alliance with a leading commercial nursery.</li><li>A food storage company in evaluating outbound technology licensing models and its outbound license terms.</li><li>A botanical active ingredient producer in its research collaboration agreement with a botanical ingredient biotechnology company.</li><li>An agtech company in its outbound license of its proprietary gene design platform to a biotechnology company.</li><li>A public agency in its licensing agreements for proprietary fruit varieties.</li><li>An agtech company in all forms of its commercial contracts, including university research agreements, NDAs, material transfer agreements, and evaluation agreements.</li><li>A novel infant formula company in its dozens of supply and manufacturing agreements with its ingredient suppliers and formula manufacturers.</li></ul><h5>Consumer Products</h5><ul><li>Grüns in its Series B preferred stock financing, including a $10 million primary investment at a $500 million post-money valuation led by Headline Global Growth and a $25 million secondary tender offer, with conversion of outstanding SAFEs and convertible notes.</li><li>David Protein (aka Linus Technology, Inc.), a cutting-edge brand offering high-protein, low-calorie nutrition and redefining how we think about fat, in its Series A financing and its acquisition of the company behind EPG—a plant-based fat substitute that replicates the texture and mouthfeel of traditional fat.</li><li>An adaptogenic, nootropic, functional beverage, and other companies in their third-party logistics, supply, distribution, and licensing agreements.</li></ul><h5>Clean Technology</h5><ul><li>A large non-profit in its investment decisions. </li><li>A public carbon credit investing company in its collaboration agreement with air quality monitoring company.</li><li>A venture-backed clean technology startup in its international collaboration agreements.</li><li>A venture-backed clean technology startup in its technology license and service agreement with international public energy company and other licensees.</li></ul><h5>Artificial Intelligence and Machine Learning</h5><ul><li>A cybersecurity startup in all of its customer and vendor agreements.</li><li>A hardware/software combination company in its negotiation of customer POC agreements, evaluation agreements, and commercial deployments.</li><li>An alternative legal services provider in its suite of customer agreements.</li><li>A large consulting companies in their evaluation of AI terms for both vendors and customers.</li></ul>

Matthew Ferry

Jessica Kwok is an associate in the Technology Transactions Group of Morrison Foerster’s San Diego office.Jessica’s practice focuses on transactions and counseling involving the acquisition, development, licensing, and transfer of intellectual property and technology. She leverages her background in life sciences to counsel clients across a variety of industries, such as biotechnology, pharmaceuticals, and software and cloud services.Jessica has experience drafting and negotiating a broad range of intellectual property and commercial agreements, including technology, software, and patent licenses, research and development collaborations, services agreements, and clinical trial agreements. She also advises on the intellectual property and technology aspects of mergers and acquisitions and other corporate transactions.Jessica earned her J.D. from the University of California, Berkeley, School of Law, where she was elected to the Order of the Coif and served as a notes editor for the California Law Review. She earned her B.S. summa cum laude from the University of California, Davis. Prior to law school, Jessica worked as a research associate at a metabolomics core laboratory.

Jessica Kwok

Morgan Rhodes Logan is an associate in Morrison Foerster’s Boston office and a member of the firm’s Technology Transactions Group.Morgan advises emerging and established companies in the life sciences industry on structuring and negotiating various intellectual property and commercial transactions, including collaborations, licensing, clinical trials, mergers, and acquisitions. Morgan has worked with biotechnology, therapeutics, diagnostics, medical devices, digital health, and agricultural technology companies.Recognized by Massachusetts Lawyers Weekly on its Excellence in the Law list of Up & Coming Lawyers, Morgan’s experience includes representing founders who are licensing technology from academic institutions, as well as companies experiencing high-value exits, including IPOs and acquisitions.Morgan maintains an active pro bono practice focused on family law, immigration, and asylum matters. She has been recognized for her commitment to public service through multiple pro bono awards.Morgan earned her J.D. from the University of Michigan Law School, where she completed externships with Invest Detroit and the Mercury Fund. She received her B.A. in science & society, with a focus on cognitive neuroscience, from Brown University.

Morgan Rhodes Logan

Emily Beers is of counsel in Morrison Foerster’s Capital Markets and Public Company Advisory & Governance practices. Her practice focuses on representing publicly and privately held companies in a variety of corporate and securities law matters.Emily represents both issuers and investment banks in initial public offerings, follow-on offerings, and private placements, including offerings of common and preferred equity, investment-grade debt, convertible debt, and high-yield debt. Emily also regularly advises clients with respect to liability management transactions, including tender offers, as well as M&A transactions.In addition, Emily regularly counsels companies with respect to corporate governance issues, compliance with the U.S. federal securities laws, and the requirements of the New York Stock Exchange and NASDAQ, as well as general corporate matters.Emily is recognized in IFLR1000 for Capital Markets: Debt, Capital Markets: Equity, and M&A (2021).Prior to joining Morrison Foerster, Emily worked as an associate in the capital markets practices of other international law firms in New York and London.<h4>Representative Matters</h4><ul><li>Represented the dealer managers in Shell plc’s exchange offers of up to $8.4 billion involving six series of outstanding notes and the issuance of new privately placed notes guaranteed by Shell.</li><li>Represented the underwriters in connection with the $2.35 billion offering of guaranteed notes issued by Shell Finance U.S. Inc., a subsidiary of Shell plc.</li><li>Represented the underwriters in the $450 million bond offering of Senior Notes by First Industrial, L.P., a real estate investment trust company.</li><li>Represented the underwriters in the $400 million registered offering of Senior Notes by COPT Defense Properties, L.P., a real estate investment trust.</li><li>Represented Riot Platforms, Inc. in its offering of $594.4 million of 0.75% convertible senior notes due 2030.</li><li>Represented the initial purchasers in the $345 million bond offering of 5.25% Exchangeable Senior Notes due 2028 by COPT Defense Properties, L.P.</li><li>Represented Wells Fargo Securities, Deutsche Bank Securities, and Goldman Sachs & Co. in Shell plc’s $12 billion exchange offering of Convertible Notes.</li><li>Represented Veeco Instruments Inc. (Nasdaq: VECO) in its private offering of up to $230 million aggregate principal amount of 2.875% Convertible Senior Notes due 2029. </li><li>Represented Crinetics Pharmaceuticals (Nasdaq: CRNX) in its $500 million public offering of 10,000,000 shares of its common stock. </li><li>Represented Crinetics Pharmaceuticals (Nasdaq: CRNX) in its $350 million private placement of 8,333,334 shares of its common stock. </li><li>Represented McKesson Corporation (NYSE: MCK) in its offering of $500 million of 4.250% notes due 2029 and subsequent redemption of 5.250% notes due 2026. </li><li>Represented onsemi (NYSE: ON) in its upsized $1.5 billion private offering of 0.50% Convertible Senior Notes.</li></ul><ul><li>Represented Sprint Corp. and SoftBank Group Corp., the controlling shareholder of Sprint, on the all- stock merger of Sprint and T-Mobile US Inc. The total implied enterprise value for Sprint in the transaction was approximately $59 billion and the aggregate for the combined company enterprise value was approximately $146 billion.</li><li>Represented onsemi (NASDAQ: ON) in its Rule 144A offering of $1.5 billion 0.5% Convertible Senior Notes due 2029; in its Rule 144A offering of $700 million 0% Convertible Senior Notes due 2027; and in its Rule 144A offering of $700 million 3.875% Senior Notes due 2028.</li><li>Represented The Chemours Company (NYSE: CC) in its Rule 144A offering of $650 million 4.625% Senior Notes due 2029; in its Rule 144A offering of $800 million 5.750% Senior Notes due 2028 and concurrent tender offers to purchase all or a portion of its outstanding Senior Notes and related consent solicitations; and in its registered offering of €450 million 4.000% Senior Notes due 2026 and concurrent tender offers to purchase all or a portion of its outstanding senior notes and related consent solicitations.</li><li>Represented McKesson Corporation (NYSE: MCK) in its registered offering of $500 million 5.250% Notes due 2026; in its registered offering of $500 million 1.300% Senior Notes due 2026 and related tender offer to repurchase a portion of its outstanding senior notes; and in its registered offerings of $700 million 3.650% Notes due 2020 and $400 million 4.750% Notes due 2029 and concurrent tender offers to purchase a portion of its outstanding senior notes and related consent solicitations.</li><li>Represented BlackBerry Limited (NYSE: BB) in its $200 million Rule 144A offering of convertible notes. </li><li>As designated underwriters’ counsel to Royal Dutch Shell Plc, represented the underwriters in connection with registered offerings of more than $30 billion of fixed and floating rate notes by Shell International Finance, the U.S. financing subsidiary of Royal Dutch Shell Plc.</li><li>Represented Southwest Gas Holdings, Inc. (NYSE: SWX) in its defense against a hostile tender offer and proxy contest by Carl Icahn, and in its subsequent registered offerings of common stock and debt. </li><li>Represented Unity Software Inc. (NYSE: U) in its stock-for-stock merger with ironSource, Ltd. for an approximate value of $4.4 billion.</li><li>Represented the underwriters in connection with the registered offering of $5 billion of notes by Novartis Capital Corporation, the U.S. financing subsidiary of Novartis AG.</li><li>Represented Vontier Corporation (NYSE: VNT) in its $1.6 billion 144A offering of Senior Notes and its $1.6 billion registered exchange offer.</li><li>Represented the placement agent in connection with the $50 million private offering of senior secured notes by Newport Realty Trust, a private mortgage REIT, the private placement of $36.5 million aggregate principal amount of 7.5% Senior Unsecured Notes due 2025 issued by NextPoint Real Estate Finance Operating Partnership, L.P., the operating partnership subsidiary of NexPoint Real Estate Finance, Inc. (NYSE: NREF), and the private placement of $42.25 million aggregate principal amount of its 7.00% Senior Unsecured Notes due 2026 issued by Pelorus Fund REIT, LLC.</li><li>Represented Veeco Instruments Inc. (NASDAQ: VECO) in its registered offering of $300 million 2.70% Convertible Senior Notes due 2023.</li><li>Represents the sales agents in connection with Equity Residential’s (NYSE: EQR) at-the-market equity offering; as designated underwriters’ counsel, represented the underwriters in connection with registered offerings by Equity Residential’s operating partnership, ERP Operating Limited Partnership, of an aggregate of $1.25 billion of notes.</li><li>Represented Whole Foods Market, Inc. (NASDAQ:WFM) in its $1.0 billion Rule 144A/Regulation S offering of 5.200% Senior Notes due 2025.</li><li>Represented the underwriters in connection with Community Healthcare Trust Incorporated’s (NYSE: CHCT) approximately $136.6 million initial public offering and in subsequent follow-on offerings.</li><li>Represented Inovalon Holdings, Inc. (NASDAQ: INOV) in its approximately $685 million initial public offering.</li></ul>

Emily Beers

Tyler Miller is a corporate associate in the firm's New York office.Tyler’s practice focuses on representing public and private companies in corporate transactions, securities regulation, and governance matters. Tyler advises on domestic and cross-border mergers and acquisitions and private equity transactions in various industries, including technology and life sciences. He also represents issuers and underwriters in connection with capital markets transactions, including initial public offerings, debt and equity offerings, and SPAC transactions.Prior to joining Morrison Foerster, Tyler was a summer associate in the firm’s New York and Tokyo offices during the summer of 2019.Tyler earned his J.D. at the University of Michigan Law School, where he was an associate editor for Michigan Business & Entrepreneurial Law Review. During that period, he also studied abroad at Amsterdam Law School in the Netherlands.<h4 dir="ltr">Representative Experience</h4><ul><li>Arm Holdings plc, the world’s leading semiconductor IP company, in its blockbuster $5.22 billion USD IPO on Nasdaq, the largest IPO of 2023.</li><li>Crinetics Pharmaceuticals in multiple transactions, including an upsized $500 million public offering of common stock and a $350 million at-the-market equity offering.</li><li>Alexandria Real Estate Equities, Inc. in numerous public offerings of debt and equity, resulting in proceeds totaling over $8 billion.</li><li>Qatalyst Partners as financial advisor in multiple transactions, including (i) Zuora, Inc.’s $1.7 billion sale to Silver Lake and GIC, (ii) WalkMe Ltd.’s $1.5 billion sale to SAP SE, (iii) HashiCorp, Inc.’s $6.4 billion sale to IBM, (iv) ANSYS, Inc.’s $35 billion sale to Synopsys, Inc., (v) New Relic, Inc.’s $6.5 billion sale to Francisco Partners and TPG, (vi) Coupa Software Incorporated’s $8 billion sale to Thoma Bravo, (vii) Zendesk, Inc.’s $10.2 billion sale to an investor group led by Permira and Hellman & Friedman, and (viii) Anaplan, Inc.’s $10.7 billion sale to Thoma Bravo.</li></ul><ul><li dir="ltr">Infineon Technologies AG in the sale of its HiRel DC-DC converter business to Micross Components, Inc.</li><li dir="ltr">Unity Software Inc. in its all-stock $4.4 billion acquisition of ironSource and in its concurrent $1 billion PIPE investment by Silver Lake and Sequoia.</li><li dir="ltr">Endurance Acquisition Corp. in its $200 million initial public offering and subsequent $813 million business combination with SatixFy Communications, Ltd. (NASDAQ: SATX).</li><li dir="ltr">Vimian Group AB in its acquisition of the assets of New Generation Devices, Inc.</li><li dir="ltr">Antarctica Capital in multiple transactions, including its acquisition of a controlling interest in Descartes Labs.</li><li dir="ltr">Solomon Partners as financial advisor to Aries I Acquisition Corporation in its business combination with Infinite Assets, Inc.</li><li dir="ltr">Steadfast Apartment REIT, Inc. in its merger with and into Independence Realty Trust, Inc. (NYSE: IRT), with IRT surviving as the continuing public company.</li><li dir="ltr">Lyons Magnus in its acquisition of Phillips Syrups and Sauces.</li><li dir="ltr">Axalta Coating Systems in its acquisition of U-POL Holdings Limited for approximately $590 million.</li><li dir="ltr">BofA Securities, J.P. Morgan Securities, and Deutsche Bank Securities in the underwritten secondary offering of shares of BrightSpire Capital, Inc. (NYSE: BRSP) by a stockholder affiliated with DigitalBridge Group, Inc. (NYSE: DBRG).</li><li dir="ltr">Honey Birdette, the fast-growing, luxury lingerie and lifestyle brand, and its sellers, in its $333 million sale to PLBY Group, Inc. (NASDAQ: PLBY), a leading pleasure and leisure lifestyle company and owner of Playboy magazine.</li><li dir="ltr">Verisem BV and Paine Schwartz Partners in connection with the sale of Verisem to Syngenta’s vegetable seeds business, part of Syngenta Group.</li><li dir="ltr">Rakuten Medical in its $166 million Series D preferred stock financing.</li></ul>

Tyler Miller

Michael Schulman is a partner in the firm’s Global Employment and Labor Group and co-head of the firm’s Washington, D.C. Litigation Department.Michael regularly advises clients in connection with important workforce-related matters, including hiring and negotiating employment agreements for senior executives, sensitive executive separations, internal workplace investigations, employment claims and disputes, and employment issues arising in the context of mergers, acquisitions, bankruptcies and other corporate transactions. Michael is known for using a pragmatic, efficient, and results-oriented approach, focused on achieving his clients’ desired business outcomes.Michael regularly guides clients through complex workforce issues, including, for instance allegations of workplace misconduct; restrictive covenant drafting, enforcement, and strategic evaluation; worker classification and wage-and-hour compliance practices; and the unique issues that arise in a unionized workplace. Michael’s experience covers a broad range of employment and labor laws at the federal, state, and local level, including Title VII of the Civil Rights Act of 1964, Section 1981 of the Civil Rights Act of 1866, the Americans with Disabilities Act, the Age Discrimination in Employment Act, the National Labor Relations Act, the Fair Labor Standards Act, the Fair Credit Reporting Act, the Uniformed Services Employment and Reemployment Rights Act, the Worker Adjustment and Retraining Notification Act, the Defend Trade Secrets Act, and corresponding state and local laws.Michael has unique experience addressing labor and employment matters that arise in connection with corporate transactions, particularly for private equity firms. Michael has represented clients in over 2,000 transactions, including many large-scale multinational mergers, acquisitions, and asset carve-outs. He regularly conducts acquisition-related labor and employment due diligence and advises clients on the employment and workforce integration or separation implications of mergers, acquisitions, sales, and financings.In the litigation context, Michael represents employers in U.S. federal and state court litigation, administrative agency proceedings, and arbitrations arising out of alleged labor and employment law violations. Michael defends employers against actions brought by government agencies, such as the Equal Employment Opportunity Commission and Department of Labor, as well as actions initiated by current and former employees. He also prosecutes suits against former employees and their new employers for breach of restrictive covenants.

Michael Schulman

Niki Hendi is an associate in Morrison Foerster’s Washington, D.C. office and a member of the firm’s Litigation Group.Her practice focuses on employment matters.Prior to joining the firm, Niki was a summer associate in the New York office. She also spent time as a Criminal Division intern at the U.S. Attorney’s Office for the Southern District of New York. While at law school, Niki was an assistant online editor of the Virginia Journal of International Law.Niki earned her J.D. from the University of Virginia School of Law and her B.A. in economics and foreign affairs at the University of Virginia.

Niki Hendi

Josh Lerner is a partner in the Executive Compensation + Benefits Group based in the New York office of Morrison Foerster.Josh advises clients on all matters involving the compensation of senior executives, including employment, change in control, equity compensation, and severance arrangements.He counsels public and private companies on executive compensation issues in a range of corporate transactions, restructurings, and financings. He has experience designing, drafting, and negotiating employment agreements and administering equity incentive plans and awards. He also works regularly with public companies on compensation-related disclosures and corporate governance matters, including Securities Exchange Act of 1934 reports. Josh earned his J.D. from Columbia Law School where he was a senior articles editor of the Columbia Business Law Review.<h4>Representative Matters</h4><ul><li>Snow Software, a technology intelligence platform, on its acquisition by Flexera Software, a data-oriented SaaS solution company.</li><li>U.S. Silica Holdings, a global industrial minerals and logistics leader, in its $1.85 billion sale to entities affiliated with Apollo Global Management.</li><li>Rivian Automotive in the formation of an equally controlled and owned joint venture with Volkswagen Group to create next generation software-defined vehicle (SDV) platforms to be used in both companies’ future electric vehicles.</li><li>Palladium Equity Partners, in the $695 million sale of its majority interest in Trachte, a leading provider of highly engineered protection and control buildings with mission critical applications, to nVent Electric plc, a leading global provider of electrical connection and protection solutions.</li><li>The rock band KISS and its co-founders Gene Simmons and Paul Stanley in the sale of substantially all rights related to KISS to Pophouse Entertainment.</li><li>McGrath RentCorp, leading provider of temporary and permanent space solutions, in its $3.8 billion acquisition by WillScot Mobile Mini Holdings Corp., a leader in innovative temporary space solutions.</li><li>Astellas Pharma in its acquisition of Propella Therapeutics, a biopharmaceutical company that combines medicinal chemistry with lymphatic targeting to create new oncology drugs.</li><li>SoftBank in connection with its $375 million acquisition of Berkshire Grey, a robotic automation company that went public via a SPAC merger in 2021.</li></ul><ul><li>Grant Thornton, one of America’s largest audit, tax, and advisory firms, in the sale of its Public Sector Advisory practice to Guidehouse, a portfolio company of Veritas Capital and leading global provider of consulting services to the public sector and commercial markets.</li><li>MTY Food Group, a leading franchisor in the North American restaurant industry, in its $200 million acquisition of BBQ Holdings, a franchisor and operator of fast casual dining.</li><li>Odevo AB, a Swedish company and a portfolio company of private equity client Fidelio Capital, in connection with its acquisition of KW Property Management & Consulting, LLC, a Florida-based company that provides property management services to homeowner associations, condominium boards, cooperative boards and townhome communities. </li><li>Tinicum and its portfolio company TSL Engineered Products in the sale of Advantek, a leading provider of highly engineered carrier tape and associated protective packaging products, to Cornell Capital.</li></ul>

Joshua Lerner

Andre Amorim is an associate in the New York office and a member of the firm’s Executive Compensation and Benefits practice.Andre’s practice focuses on a wide range of compensation and benefits matters. He advises both public and private companies on tax and securities law issues in connection with complex corporate transactions, including mergers and acquisitions, financings, and initial public offerings. He also advises employers and executives in the negotiation, design, and implementation of employment, severance, change in control, deferred compensation, equity, and other incentive compensation plans and arrangements.Prior to joining the firm, Andre advised on executive compensation and employee benefits law at another multinational law firm. He was also previously with Ernst & Young’s People Advisory Services Department, where he focused on various executive compensation and employee benefits issues with respect to foreign and domestic equity-based incentive plans, long-term incentive plans, ERISA and Affordable Care Act compliance, and qualified retirement benefit plans.Andre earned his B.A. in economics from Fordham University and his J.D. from Fordham University School of Law.

Andre Amorim

Sarah is an associate in the Executive Compensation + Benefits practice of Morrison Foerster’s San Francisco office.Prior to joining the firm, Sarah was a Summer Associate in the San Francisco office. Before that, she was a Student Legal Honors Extern for the U.S. Securities & Exchange Commission in Washington, D.C. She also spent time as a Judicial Extern at the U.S. District Court in Phoenix, Arizona.Sarah earned her J.D., cum laude, at Sandra Day O’Connor College of Law at Arizona State University, where she was an editor of the Arizona State Law Journal. She also holds a B.A. from the University of California, Los Angeles.

Sarah Doberneck

Karen Potter, Ph.D., J.D., is a nationally recognized patent attorney and leader of Morrison Foerster’s Cell and Gene Therapy Patent practice in San Diego, California. With over 20 years of experience in life sciences intellectual property law, Karen specializes in patent strategy, prosecution, and portfolio management for biotechnology and pharmaceutical companies worldwide.Karen’s technical background in cellular and molecular biology and immunology uniquely positions her as a trusted advisor for innovators in:<ul><li>Cell and gene therapies (including T cell, Natural Killer cell, stem cell, gene-based, and epigenetic therapies)</li><li>Immunotherapies (antibody and protein-based therapies)</li><li>Virus and vaccine therapies</li><li>Companion diagnostics and diagnostic assays</li><li>Protein therapeutics and bioassays</li></ul>Karen leads and mentors a multidisciplinary team of patent attorneys, agents, and scientific analysts, delivering strategic and comprehensive intellectual property services. Her practice includes:<ul><li>U.S. and international patent preparation and prosecution</li><li>Patent portfolio development and management</li><li>Patentability and freedom-to-operate analyses</li><li>Patent term extension strategies</li><li>Due diligence for investors and M&A transactions</li><li>Strategic counseling for startups, emerging, and established life sciences companies</li></ul>Karen is widely recognized for her ability to deliver pragmatic, creative patent solutions tailored to the unique needs of life sciences clients. She has been honored by publications for her leadership and innovative approach in biotechnology patent law.Before her legal career, Karen completed postdoctoral research at the La Jolla Institute for Allergy and Immunology and earned her Ph.D. in cellular and molecular biology from Duke University. Her scientific research has been published in leading peer-reviewed journals and presented at national conferences.

Karen Potter

Sierra Lear focuses her practice on patent drafting and prosecution, with an emphasis on genetics, bioengineering, and neuroscience.Prior to joining Morrison Foerster, Sierra was an NSF graduate research fellow at Gladstone Institutes, where her research focused on extending the capabilities of DNA writing tools to improve medicine. In this role, she gained experience working with molecular recording technology and plasmid- and RNA-based strategies to enable precise gene editing. Sierra previously served as an intern in Gladstone Institutes’ Intellectual Property and Legal Affairs Department, where she performed due diligence for technology licensing and reviewed material transfer agreements and contracts. Sierra also previously served as a medical genetics’ instructor at San Francisco State University’s post-baccalaureate program.Sierra earned her Ph.D. in bioengineering from UC Berkeley-UC San Francisco and her B.S in engineering, chemical engineering, and neuroscience from Tulane University. As a doctoral student, Sierra was editor-in-chief of the Berkeley Science Review.

Sierra Lear

Patent Agent

Ivy Fernandes is a Patent Agent at Morrison Foerster, where she focuses on patent drafting and prosecution in areas related to molecular and cellular biology, immunotherapies, and genetics.Prior to joining Morrison Foerster, Ivy conducted advanced research in cardiac development, using advanced imaging techniques, CRISPR-Cas9, and RNA sequencing to lead gene expression analysis projects. Ivy earned her B.S. in Bioengineering from Santa Clara University and her Ph.D. in Biological Sciences from the University of California, San Diego.

Ivy Fernandes

Keren Shoshani-Haye is a Scientific Analyst focused on life sciences intellectual property and patent strategy for biotechnology innovations. She supports patent preparation, patentability analysis, and prior art evaluation.Dr. Shoshani-Haye has research experience across academia and industry. Her scientific background spans molecular biology, functional genomics, epigenetics, advanced microscopy, and computational data analytics. She has authored multiple peer-reviewed publications and applied her professional background to analyze complex scientific data, evaluate patentability, and support strategic patent drafting and prosecution.Keren’s graduate and post-graduate research focused on developmental neurobiology and the molecular basis for affective disorders, where she developed and applied advanced sequencing techniques, in vivo models, and bioinformatic analysis. She has also developed experience in innovation evaluation and technology strategy through the National Forum for Bio-Innovators, assessing scientific novelty, competitive positioning, and commercial potential of biologics-based technologies.Dr. Shoshani-Haye earned her Ph.D. and M.Sc. in molecular neuroscience from the Weizmann Institute of Science and her B.Sc. in cognitive sciences and life sciences from the Hebrew University of Jerusalem, graduating with distinction.

Keren Shoshani-Haye

Scientific Analyst

Aaron Fountain is a Chambers-ranked patent litigation and intellectual property trial lawyer and Practice Group Lead of Morrison Foerster’s Intellectual Property Litigation Group. He represents clients in high-stakes patent disputes and frequently serves as lead counsel in the nation’s most active patent litigation venues, including the U.S. District Courts for the Western and Eastern Districts of Texas and the District of Delaware, as well as before the U.S. International Trade Commission (ITC), the Patent Trial and Appeal Board (PTAB), and the U.S. Court of Appeals for the Federal Circuit.Aaron’s experience spans patent infringement litigation, ITC investigations, inter partes review (IPR) proceedings and other disputes before the U.S. Patent and Trademark Office (USPTO), and Federal Circuit appeals. He also counsels clients on patent portfolio management and strategy.A former research scientist, Aaron brings a deep technical perspective to complex patent disputes. Before practicing law, he focused on instrumentation design and method development for proteomics research. His scientific background enables him to quickly understand complex technologies and translate highly technical concepts into clear, persuasive arguments for judges, juries, and the PTAB.Aaron’s patent litigation experience spans a wide range of technologies and industries, including:<ul><li>Life sciences and healthcare: biologics, molecular diagnostics, medical devices, and topical pharmaceuticals</li><li>Technology and electronics: semiconductors, consumer electronics, software, and telecommunications infrastructure</li><li>Industrial technologies: specialty chemicals, automotive technologies, mining equipment, and oil field services</li></ul>Aaron clerked for the Honorable Arthur J. Gajarsa of the U.S. Court of Appeals for the Federal Circuit and the Honorable Harry Lee Hudspeth of the U.S. District Court for the Western District of Texas. He also interned for the Honorable Ewing Werlein, Jr. of the U.S. District Court for the Southern District of Texas.In addition to his recognition by Chambers USA, Aaron has been recognized for his intellectual property work by The Legal 500, Law360, and Super Lawyers.Aaron maintains an active pro bono practice, including successfully serving as lead appellate counsel for veterans before the U.S. Court of Appeals for Veterans Claims and representing lawful permanent residents before the Board of Immigration Appeals. He is a member of the Federal Circuit Bar Association, the Austin Intellectual Property Lawyers Association, and the American Intellectual Property Law Association.

Aaron Fountain

Practice Group Lead, IP Litigation

Hunter Ubersox is an associate in Morrison Foerster’s Intellectual Property Litigation Group based in the firm’s Austin office.Hunter’s practice focuses on patent litigation.Before joining Morrison Foerster, Hunter served as an engine development engineer at General Motors, where he executed oil circuit and ventilation development testing for a production-intent internal combustion engine program, including devising custom testing methods to replicate issues, determine root-causes, and validate solutions. He wrote technical reports certifying engine oil circuit and crankcase ventilation performance and compliance with program technical specifications in preparation for mass production. Hunter received his J.D. with honors from the University of Texas School of Law, where he was a member of the Order of the Coif. While in law school, he was an associate editor for Texas Law Review. Hunter received his B.S. in Mechanical Engineering with highest honors from Georgia Institute of Technology.

Hunter Ubersox

Melissa Crespo advises companies on high-stakes privacy, cybersecurity, and technology matters. Clients rely on her to quickly identify what matters, assess risk, and develop practical, defensible solutions. She regularly advises on matters involving emerging technologies and laws, and business models that do not fit neatly within existing frameworks.Melissa’s practice brings together counseling, regulatory investigations, strategic transactions, and incident response. That perspective informs every aspect of her advice. She understands how decisions made during product development may later be viewed by regulators, how privacy and cybersecurity issues can affect deal value and integration, and how policies and controls perform when tested by an incident.Melissa advises companies across the lifecycle of data use, from building privacy compliance programs and designing consumer-facing products, to commercializing data, as well as on the development and deployment of artificial intelligence.Drawing on her experience with state privacy laws and the FTC’s consumer protection authority, Melissa helps clients structure data-driven products, advertising, analytics, and monetization strategies in ways that are practical and defensible. She has substantial experience with children’s and teen privacy, online safety, age assurance, parental consent, and products designed for younger users.She has particular depth in health privacy and security. She advises healthcare, life sciences, digital health, and technology companies on HIPAA and other laws governing health information, including in connection with emerging technologies, research, digital advertising, interoperability, information blocking, and new uses of health data.Melissa regularly represents companies in privacy, cybersecurity, and consumer protection investigations before the Federal Trade Commission, the U.S. Department of Health and Human Services Office for Civil Rights, state attorneys general, and international regulators. She helps clients develop the factual and legal record, anticipating how regulators will assess a company’s conduct and decision-making, and positioning clients for an effective resolution.Her transactional practice includes advising on privacy and cybersecurity issues in acquisitions, investments, and other strategic transactions. That work sharpens her understanding of which issues can affect value, impede growth, or become post-closing problems, and makes her a more effective counselor to companies developing products, compliance programs, and long-term data strategies.Melissa also leads clients through significant data security incidents. She coordinates legal strategy from investigation and notification through remediation and regulatory response, giving her practical insight into how privacy and security decisions hold up under pressure.Melissa serves on Morrison Foerster’s Life Sciences Steering Committee and Interactive + Digital Media Steering Committee, reflecting her work across regulated industries, emerging technologies, and consumer-facing products.

Melissa Crespo

Darcy Black advises clients across industries on privacy, cybersecurity, and technology matters, including cyber incident response, privacy compliance, information governance, transaction diligence, and emerging issues involving artificial intelligence. She regularly guides organizations through cybersecurity incidents, helping clients assess legal obligations, coordinate forensic investigations, prepare regulatory notifications, and manage communications with regulators and other stakeholders.Darcy also advises clients on compliance with U.S. and international privacy laws, including the General Data Protection Regulation (GDPR), the California Consumer Privacy Act (CCPA/CPRA), the Illinois Biometric Information Privacy Act (BIPA), the Children’s Online Privacy Protection Act (COPPA), and emerging artificial intelligence laws and regulations, including the Colorado AI Act and California’s Automated Decision-Making Technology (ADMT) regulations. She also helps clients develop and implement privacy compliance programs, including privacy notices, cookie disclosures, vendor and data processing agreements, and incident response plans. In addition, she supports clients on privacy and cybersecurity diligence for mergers and acquisitions.Darcy earned her J.D. from Boston University School of Law, where she was a member of the Lawyers in Technology and Business Law Society.Before law school, Darcy served as a Digital Assurance and Transparency associate at PricewaterhouseCoopers, focusing on information security and data management for System and Organization Controls reports. She earned her B.S. summa cum laude in business administration from Boston University Questrom School of Business, where she participated in the Questrom Honors Program.

Darcy Black

Brigid is a food, drug, and medical device lawyer who counsels life sciences companies on a wide range of U.S. Food & Drug Administration pre- and post-market regulatory issues.As the lead of our FDA + Healthcare Regulatory and Compliance Group, Brigid practices across the spectrum of FDA-regulated products, including medical devices, drugs, biologics, cell and gene therapies, food, cosmetics, dietary supplements, tobacco, laboratory-developed tests, in vitro diagnostics, radiation-emitting electronic products, combination products, and products that may not fit neatly into any of these categories. Accordingly, she counsels established and start-up companies in life sciences, healthcare, and consumer products on a wide range of FDA pre- and post-market regulatory issues. Brigid also frequently advises innovative product developers on threshold FDA jurisdictional questions and develops strategies for approval and marketing, while identifying and mitigating regulatory risks.In her day-to-day practice, Brigid advises on:<ul><li>product development and FDA’s pre-authorization requirements;</li><li>advertising and promotion of FDA-regulated products;</li><li>clinical trials regulation, including strategic advice for sponsors in receipt of a clinical hold;</li><li>responses to warning letters, Form 483s, import alerts, and FDA enforcement actions;</li><li>informal and formal dispute resolution for high-stakes issues;</li><li>compliance with FDA regulatory requirements such as current good manufacturing practice (GMP), quality system regulation (QSR), food safety preventive controls, adverse event reports, product recalls, radiological health issues, risk evaluation and mitigation strategies (REMS), pharmacy compounding and the new track-and-trace regulations for prescription drugs; and</li><li>technical legal questions involving the Food, Drug and Cosmetic Act (FDCA), the Public Health Service Act (PHSA), Federal Advisory Committee Act (FACA), Freedom of Information Act (FOIA), and the Administrative Procedure Act (APA).</li></ul>Brigid also has experience in the development, regulation, and procurement of medical countermeasures (MCMs) against chemical, biological, radiological, and nuclear (CBRN) threats and pandemic infectious diseases, including animal rule approvals and special incentives for the development of MCMs.Complementing her focus on FDA regulatory law, Brigid has a strong litigation background and has served as FDA counsel in product liability cases, civil litigation, international arbitration, and FDA enforcement proceedings. She particularly enjoys providing clients with advice that integrates technical, legal, and political considerations.Brigid maintains an active pro bono practice focused primarily on reproductive health and especially enjoys working with inventors who aim to improve health outcomes for mothers and infants in the peri- and post-natal period. She has represented several clients before the Social Security Administration in appealing denials of applications for disability benefits. She has also worked on several appeals in criminal cases in the District of Columbia.Brigid is a graduate of the University of Tulsa, where she earned her B.S. in biochemistry before attending law school at Stanford Law School. Prior to law school, Brigid worked as an Environmental Policy Analyst in the Office of the Secretary at the U.S. Department of Transportation. She has also worked as a benchtop scientist in a number of laboratories, including FDA’s National Center for Toxicological Research.<h4>Representative Experience</h4><ul><li>Counseled online marketplaces regarding FDA compliance and enforcement for a variety of products.</li><li>Advised development-stage companies on regulatory considerations and FDA engagement strategies related to development and launch of products based on disruptive technologies.</li><li>Advised consumer technology companies with respect to potential FDA regulation under the medical device provisions of the FDCA;</li><li>Served as FDA regulatory counsel to clients evaluating compliance issues under reporting provisions of Corporate Integrity Agreements and related negotiated resolutions of government investigations.</li><li>Helped a large, publicly traded drug company comply with the FDA’s new track-and-trace pedigree requirements for prescription drugs.</li><li>Led regulatory team on numerous initial public offerings (IPO), stock and asset purchase agreements, acquisitions, mergers, and other transactions for life science company.</li><li>Provided strategic advice, conducting regulatory assessments and negotiating key FDA-related terms in connection with due diligence for transactions and post-acquisition integration activities.</li><li>Developed policy positions related to FDA regulation of laboratory-developed tests (LDTs) for multiple clients in this space.</li><li>Represented manufacturers in matters involving regulatory letters, inquiries, advisory comment proceedings, competitor complaints and citizen petitions focused on their products and policy issues affecting their strategic priorities.</li><li>Advised on issues related to promotion of drugs and medical devices, including communication of pharmacoeconomic/healthcare economic information (HCEI), communications by medical science liaisons (MSLs).</li><li>Provided solutions-oriented advice to development-stage companies confronting FDA regulatory issues for the first time, including good clinical practices (GCP), investigator-initiated research (IIR), pre-approval communications and strategies for obtaining FDA approval.</li><li>Collaboratively advised client on FDA, ethical, and product liability issues associated with early termination of a clinical study involving an implanted medical device.</li></ul>

Brigid Bondoc

Megan focuses her practice on healthcare regulatory, operational, and transactional matters. As a member of the FDA + Healthcare Regulatory and Compliance Group, Megan provides guidance to participants in and across the healthcare industry, including digital health companies, healthcare systems, and healthcare startups. She helps companies develop, evaluate, and implement innovative business strategies in consideration of the complex, multijurisdictional regulatory requirements governing the healthcare industry.Megan also helps guide companies through various transactions, including corporate acquisitions, integrations, and affiliations, establishing management service organizations, and drafting professional services arrangements. She provides valuable guidance on issues pertaining to the Corporate Practice of Medicine, HIPAA compliance, day-to-day operational matters, issues concerning Medicare, Medicaid, and commercial payor reimbursement, drug-pricing, as well as licensure, certification, and scope of practice requirements. She counsels companies on issues pertaining to fraud and abuse concerns, including compliance with the Physician Self-Referral Law (the Stark Law), the Anti-Kickback Statute (AKS), the Eliminating Kickbacks in Recovery Act (EKRA), and the False Claims Act (FCA).Prior to joining Morrison Foerster, Megan practiced at full-service firms in D.C., as well as at a boutique healthcare firm in Virginia. Megan received her J.D. from the Emory University School of Law and earned her B.A. from the University of Virginia. She is an active member of the American Health Lawyers Association and has been recognized in Best Lawyers: Ones to Watch® in America since 2021.

Megan Dhillon

Atiq Chowdhury is an associate in the FDA + Healthcare Regulatory and Compliance practice, where he advises FDA-regulated companies on a wide range of regulatory, enforcement, and compliance matters. He counsels pharmaceutical, medical device, and food companies on FDA regulatory requirements, fraud and abuse issues, states’ corporate practice of medicine and licensing matters. Atiq focuses on assisting clients in the diagnostics, software as a medical device, mobile medical applications, and medical technology fields in becoming compliant with the Federal Food, Drug, and Cosmetic Act and the Clinical Laboratory Improvement Amendments. Prior to joining Morrison Foerster, Atiq practiced at other leading international law firms. For more than a decade, he also worked in reviewer and policy roles at the U.S. Food and Drug Administration (FDA). In these roles, he reviewed Premarket Approval notifications and applications, Investigational Device Exemptions, Q-Submission requests, and promotional and compliance issues, and contributed to guidance documents and other agency policy priorities. He also served as a Commissioned Corps Officer in the U.S. Public Health Service (PHS) for nearly a decade. While at the FDA, Atiq was honored by the FDA Center for Devices and Radiological Health (CDRH) with the Special Recognition Award for MDUFA III Assessment and Implementation and the Excellence in Compliance and Enforcement Award. He also received Commendation and Citation medals from the PHS for his contributions to approving and clearing first-of-their-kind diagnostic and therapeutic devices.Atiq’s experience has included, for example:<ul><li>Assisting clients with interactions between FDA and other global health authorities related to drug and device submissions (e.g., Investigational New Drugs, New Drug Applications, Q-Submissions, 510k applications, Investigational Device Exemptions, De Novo submissions, and Premarket Approval applications).</li><li>Advising clients on FDA regulations and global regulatory strategies related to the development of drug, device, and combination product marketing applications which include software applications, companion diagnostics, diagnostic tests, biomarkers, and digital health tools.</li><li>Advising medical device and pharmaceutical facilities on preparation for FDA inspections or responding to FDA Form 483 observations, import alerts, and warning letters, as well as developing site remediation work plans.</li><li>Performing gap assessments for device and drug manufacturers across a range of quality systems, including complaint handling, corrective and preventive actions, good documentation practices, supplier management, and adverse event safety reporting.</li><li>Supporting internal investigations concerning alleged cGMP/QSR compliance violations at FDA-regulated manufacturing facilities based in the United States, Europe, and Asia.</li><li>Representing and advising large healthcare and life sciences companies, as well as small biotech and medtech companies, on acquisitions, mergers, joint ventures, and other arrangements.</li></ul>

Atiq Chowdhury

Locke is a partner in MoFo’s Government Contracts & Public Procurement practice. He has been recognized by Chambers USA for his “proficiency across the government contracts space,” with sources commending his deep experience in Intellectual Property and Data Rights.Locke counsels clients across industries through the full lifecycle of delivering technology and licensing software to U.S. federal, state, and local governments, and performing government-funded R&D through contracts, grants, cooperative agreements, and other vehicles such as other transactions (OTs/OTAs), cooperative research and development agreements (CRADAs), and the Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs. He provides strategic advice for asserting, protecting, and enforcing patents, data rights, and other intellectual property under the Federal Acquisition Regulation (FAR) and the Defense Federal Acquisition Regulation Supplement (DFARS) and the Bayh-Dole Act, before statutory agencies such as NASA and the Department of Energy, and in engagements with OT consortia, federal laboratories, and federally funded research and development centers (FFRDCs). He is a skilled negotiator of commercial and noncommercial licensing agreements, contracts and subcontracts, joint venture agreements, and teaming agreements. As a litigator, Locke represents clients in bid protests, complex contract claims, data rights challenges, patent and copyright infringement suits under 28 U.S. Code §1498, trade secrets misappropriation and reverse-FOIA disputes, and civil fraud and qui tam actions under the False Claims Act. Locke also regularly advises large and small businesses, private equity firms, and entrepreneurs on the complex government contracting and IP-related issues they face in M&A and other transactional matters.Locke has repeatedly been “Recommended for Government Contracts” by The Legal 500, and in 2024 he was ranked “Up and Coming” in Government Contracts by Chambers USA. He has also been recognized as a Rising Star by Law360 and the National Law Journal.Locke is a professorial lecturer in law at the George Washington University Law School, where he teaches Government Procurement of Intellectual Property. He is a current vice-chair and former co-chair of the Intellectual Property Committee for the American Bar Association Public Contract Law Section. Locke holds a B.S. in mechanical engineering from the University of Virginia and formerly was a patent examiner for the U.S. Patent and Trademark Office. He earned his J.D. with honors from the George Washington University Law School, where he received the Patricia A. Tobin Government Contracts Award. Locke clerked for Judge Mary Ellen Coster Williams at the U.S. Court of Federal Claims.

Locke Bell

Tina Reynolds is chair of Morrison Foerster’s Government Contracts & Public Procurement practice. She represents a wide variety of government contractors including information technology, defense, biotechnology, and pharmaceutical companies, as well as research organizations and universities, with a focus on general contract counseling and compliance, intellectual property and cybersecurity matters, federal grant funding, and state and local government contracting matters.Tina routinely advises clients on:<ul><li>Contract negotiations and prime-subcontractor relationships</li><li>Sources of supply and country of origin requirements</li><li>Organizational conflicts of interest and other ethics considerations</li><li>Safeguarding of intellectual property and other proprietary interests</li><li>Licensing and data rights issues</li><li>Handling of classified materials and controlled unclassified information</li><li>Freedom of Information and Public Records Act requests</li></ul>She also conducts due diligence and other activities related to the acquisition of government contracting concerns, and drafts and negotiates teaming agreements, subcontracts, licensing agreements, and cooperative research and development agreements, Small Business Innovative Research (“SBIR”) and Small Business Technology Transfer Program (“STTR”) agreements, and other transaction authority (“OTA”) agreements.Tina’s litigation experience includes government contracts claims litigation in federal courts and before boards of contract appeals, bid protests before the Government Accountability Office and the Court of Federal Claims, and complex disputes in federal courts, including civil fraud and False Claims Act litigation, and reverse Freedom of Information Act litigation.Prior to joining Morrison Foerster, Tina worked at another large national firm and as a trial attorney in the U.S. Department of the Navy, Office of the General Counsel, Navy Litigation Office.<h4>Recent Representative Experience</h4><ul><li>Negotiated the largest CHIPS Act federal funding agreement between a multinational semiconductor corporation and the U.S. Department of Commerce. </li><li>Negotiated a prime contract and major subcontracts related to the Department of Energy’s next generation supercomputer program, including extensive IP rights and associated patent rights waivers. </li><li>Negotiated a series of other transaction authority agreements with DARPA and associated subcontracts with more than a dozen research universities on behalf of a firm biotech client, including complex IP rights allocations and material transfer agreements. </li><li>Assisting clients with the FedRAMP authorization process and the development of license agreements for software products sold to federal, state, and local government agencies. </li><li>Providing cyber incident response counseling to some of the largest companies and organizations impacted by security incidents, many involving nation state threat actors. </li><li>Advising clients on Bayh-Dole reporting of inventions and IP strategies for contracts and grants. </li><li>Conducting due diligence for major government contract mergers and acquisitions, including, for example, Salesforce’s $8 billion acquisition of Informatica and Palo Alto Networks’ $25 billion acquisition of CyberArk. </li><li>Advising clients on litigation strategy for False Claims Act matters, including those being handled by the U.S. Department of Justice (DOJ) cyber fraud initiative.</li></ul>

Tina Reynolds

Megan is a former trial attorney with the DOJ’s Antitrust Division. At Morrison Foerster, she is a partner in the Antitrust Group advising clients on their most complex and high-stakes competition matters. Her practice focuses on government investigations, merger reviews, strategic transactions, and civil antitrust litigation, particularly where enforcement, compliance, and global antitrust and regulatory risk intersect.Megan regularly counsels clients on antitrust risks arising from industry collaborations, trade associations, consortia, and other joint activities, drawing on her firsthand experience investigating and prosecuting cartel conduct. While at the Antitrust Division, Megan investigated and prosecuted federal antitrust violations, including international cartel matters involving price fixing, bid rigging, and market allocation. She now leverages that experience to help clients design, implement, and defend antitrust compliance programs, and she routinely delivers antitrust training for executives and employees.Megan also maintains a robust merger practice, advising clients at every stage of the merger review process. She develops transaction strategies, assesses and manages obligations under the Hart-Scott-Rodino Antitrust Improvements Act (“HSR Act”), and represents clients before antitrust authorities in the United States and abroad. Megan regularly represents third parties in agency reviews of transactions, including at trial.Her experience spans a wide range of industries, including telecommunications, media, technology and software, financial services, consumer products, aviation, higher education, manufacturing, agriculture, and life sciences. While at the Antitrust Division, Megan prosecuted the first individual ever extradited to the United States on an antitrust charge and earned the Assistant Attorney General’s Award for Distinguished Service for her work investigating and prosecuting international automotive parts cartels. She was also awarded the DOJ’s Outstanding Mentor Award by the Attorney General. Megan has been widely recognized by leading publications including Chambers, Global Competition Review, Bloomberg, The American Lawyer, and others. She has served as a non-governmental advisor to the International Competition Network (ICN) and has spoken at the ICN Cartel Workshop in Lisbon, Portugal. Megan is an editor of The Antitrust Source, the ABA’s online antitrust magazine, and is a member of Morrison Foerster’s global Sustainability + Corporate Responsibility Group. She also serves on the board of directors of the U.S. Sustainable Investment Forum (SIF).Before attending law school, Megan worked in the DOJ’s Office of Public Affairs, where she assisted the Assistant Attorney General for Antitrust with media strategy and served as a national spokesperson. She also worked as a paralegal in the Antitrust Division, supporting trial teams in criminal antitrust prosecutions.<h4>Representative Experience</h4><h5>Criminal and Civil Antitrust Investigations</h5><ul><li>Achieved non-prosecution protection for two healthcare companies in separate DOJ Antitrust Division criminal investigations; represented company witnesses at trial.</li><li>Obtained non-prosecution protection for a senior executive in criminal investigation into no-poach agreements in defense sector; executive testified at the criminal trial.</li><li>Completed a non-prosecution agreement for a senior executive in a DOJ criminal investigation into market allocation and bid rigging of generic drugs.</li><li>Regularly advises senior executives on DOJ antitrust criminal investigations involving allegations of price fixing, market and customer allocation, and bid rigging, and obtained non-prosecution protection for several individuals.</li><li>Represented a technology company in a Federal Trade Commission monopolization investigation.</li><li>Defended a private equity fund in a state AG investigation.</li><li>Represented an energy company in a criminal investigation.</li><li>Counseled a senior executive on an international criminal cartel investigation.</li><li>Obtained a non-prosecution agreement for a senior executive in a criminal investigation into conduct related to the hiring of employees.</li></ul><h5>Antitrust Merger Review</h5><ul><li>Obtained merger clearance for a telecommunications company in connection with a $20 billion acquisition, which closed in 2026.</li><li>Navigated ShowingTime Inc., a leading real estate showing management and market stats technology provider, through an extended review by the Federal Trade Commission of its $500 million vertical acquisition by Zillow Group.</li><li>Delivered merger clearances for Unity Technologies Corp. in connection with an asset carve-out acquisition from Weta Digital of certain assets, including its audiovisual effects development and management software tools, for a purchase price of $1.625 billion.</li><li>Advised and obtained merger clearances for Grant Thornton LLP in connection with the sale of its Public Sector Advisory practice to Guidehouse.</li><li>Represented Divvy, a leader in spend management, in its $2.5 billion stock and cash sale to Bill.com. </li><li>Supported NTT, a leading IT infrastructure and services company, in its $330 million cash sale of WhiteHat Security to Synopsys, Inc.</li><li>Represented Continental Building Products, a North American leader in wallboard and joint compound materials, in negotiations to secure antitrust approvals for its sale to Saint-Gobain. The transaction cleared without a second request investigation.</li><li>Assisted The Walt Disney Co. in its $71 billion acquisition of certain businesses from 21st Century Fox.</li><li>Represented Canadian aircraft manufacturer Bombardier in connection with the worldwide antitrust clearance of its sale of a controlling interest in the “C Series” line of commercial passenger jets to Airbus. The transaction cleared without any second-phase reviews.</li><li>Regularly assisting third parties in responding to DOJ and FTC outreach and Civil Investigative Demands in connection with merger reviews, and corporate clients with antitrust issues in complex transactions, including collaborations, joint ventures, acquisitions, and mergers.</li></ul><h5>Antitrust Litigation</h5><ul><li>Representing Beeline Loans in federal antitrust litigation alleging price fixing and information sharing in connection with use of Optimal Blue software.</li><li>Defending Otter Tail Corp. and its subsidiaries in federal antitrust litigation alleging price fixing and information sharing through third-party market newsletter.</li><li>Supporting Verizon Communications in federal antitrust litigation alleging antitrust violations brought by VoIP-Pal.</li><li>Defending BJMC Global in federal antitrust litigation alleging non-solicitation agreements and wage fixing in violation of antitrust laws.</li><li>Representing Glenmark Pharmaceuticals in a federal antitrust multidistrict litigation alleging price fixing and market allocation of generic drugs by manufacturers of generic drugs.</li><li>Assisting Nexstar Media Group, America’s largest local television and media company, in federal antitrust litigation alleging price fixing in television advertising.</li><li>Counseled a leading international financial institution in multiple, sprawling class action lawsuits alleging a global conspiracy by some of the world’s largest banks to manipulate the interbank offer rate (IBOR) benchmark for multiple currencies.</li></ul>

Megan Gerking

Brian Radigan is a partner in the Federal Tax Group at Morrison Foerster. He has a broad tax practice advising U.S. and non-U.S. clients on complex tax structuring and the tax aspects of corporate transactions.Brian advises private equity funds, startup entities, REITs, and established multinational corporations on the tax aspects of mergers and acquisitions, joint ventures, cross-border corporate restructurings, and capital markets transactions. He has a particular focus on international tax, helping clients on cross-border structure formation and tax-driven internal reorganization, navigating tax laws across multiple jurisdictions to maximize global tax efficiency.Brian regularly advises emerging companies and venture capital firms on the tax aspects of capital raises, changes to capital structure, and general tax planning, providing strategic insight and tailored tax solutions to drive tax-efficient growth. He also advises financial institutions and corporations on capital markets offerings, financial products, and FATCA compliance.Brian is Recommended for US Taxes: Non-Contentious by Legal 500 US 2024.Prior to joining Morrison Foerster, Brian spent over a decade as a senior in-house tax advisor at General Electric and, more recently, as the global head of tax at New Fortress Energy (NFE). He structured the transition of NFE from an Up-C investment of Fortress Investment Group to a multibillion-dollar, fully public company. In his in-house roles, he served as a trusted advisor to senior executives, founders, and board members on various high-profile transactions, including a $2 billion LNG infrastructure joint venture between NFE and Apollo and a $5.1 billion acquisition by NFE of Hygo Energy Transition and Golar LNG Partners, LP.